Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study

Prevalence and Correlates of Lymphatic Filariasis Infection and Its Morbidity Following Mass Ivermectin and Albendazole Administration in Mkinga District, North-Eastern Tanzania

(2020) Adam M. Fimbo et al.   Journal of Clinical Medicine

Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature

(2018) Philip J. Budge et al.   PLoS Neglected Tropical Diseases

Assessment of lymphatic filariasis prior to re-starting mass drug administration campaigns in coastal Kenya

(2017) Sammy M. Njenga et al.   Parasites & Vectors

Gender differences in the adverse events’ profile registered in seven observational studies of a wide gender-medicine (MetaGeM) project: the MetaGeM safety analysis

(2016) Emanuela Zagni et al.   Drug Design Development and Therapy

Adverse drug reactions in special populations - the elderly

(2015) E. A. Davies et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis

(2015) Edward K. Thomsen et al.   CLINICAL INFECTIOUS DISEASES

Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-Tuberculosis Drugs: A Prospective Four Arm Observational Study in Ethiopian Patients

(2014) Getnet Yimer et al.   PLoS One

Global Programme to Eliminate Lymphatic Filariasis: The Processes Underlying Programme Success

(2014) Kazuyo Ichimori et al.   PLoS Neglected Tropical Diseases

Immunology of lymphatic filariasis

(2013) S. Babu et al.   PARASITE IMMUNOLOGY

Adverse reactions following mass drug administration with diethylcarbamazine in lymphatic filariasis endemic areas in the Northeast of Brazil

(2013) Ana Wládia Lima et al.   Revista da Sociedade Brasileira de Medicina Tropical

A Review of Factors That Influence Individual Compliance with Mass Drug Administration for Elimination of Lymphatic Filariasis

(2013) Alison Krentel et al.   PLoS Neglected Tropical Diseases

Immunopathogenesis of lymphatic filarial disease

(2012) Subash Babu et al.   Seminars in Immunopathology

Adverse drug reactions caused by drug-drug interactions reported to Croatian Agency for Medicinal Products and Medical Devices: a retrospective observational study

(2011) Nikica Mirošević Skvrce et al.   CROATIAN MEDICAL JOURNAL

Coverage and compliance to mass drug administration for lymphatic filariasis elimination in a district of Kerala, India

(2011) Zinia T. Nujum   International Health

Predictors of compliance with a mass drug administration programme for lymphatic filariasis in Orissa State, India 2008

(2010) P. T. Cantey et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Current practices in the management of lymphatic filariasis

(2009) Moses J Bockarie et al.   Expert Review of Anti-Infective Therapy

Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance

(2008) Bontha V. Babu et al.   TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE

Pharmacovigilance through consumer feedback (reporting) in the mass treatment of lymphatic filariasis using diethylcarbamazine and albendazole in two districts of Sri Lanka

(2008) Sharmini Gunawardena et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH